id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9192 R31819 |
Aydin (Phenytoin) (Controls exposed to Lamotrigine, sick), 2020 | Preterm delivery (before 37 weeks of gestation) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
13.00 [0.10;1680.94] C excluded (control group) |
0/1 0/7 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9193 R31829 |
Aydin (Phenytoin) (Controls unexposed, sick), 2020 | Preterm delivery (before 37 weeks of gestation) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 7.80 [0.12;487.53] C | 0/1 2/22 | 2 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9272 R32150 |
Bank (Phenytoin) (Mixed indications), 2017 | Premature (<37 weeks gestation) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 4.60 [0.15;144.69] C | 0/3 1/36 | 1 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9186 R31764 |
Arkilo (Phenytoin), 2015 | Premature delivery | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 0.65 [0.03;14.95] C | 0/5 3/24 | 3 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9275 R32162 |
Kilic (Phenytoin) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Preterm (< 37 weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.06 [0.06;19.86] C excluded (control group) |
0/5 83/880 | 83 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9276 R32165 |
Kilic (Phenytoin) (Controls unexposed NOS) (Mixed indications), 2014 | Preterm (< 37 weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: No |
2.10 [0.11;39.05] C excluded (control group) |
0/5 33,974/676,834 | 33,974 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9277 R32168 |
Kilic (Phenytoin) (Controls unexposed, sick) (Mixed indications), 2014 | Preterm (< 37 weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 1.42 [0.08;26.49] C | 0/5 383/5,296 | 383 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9187 R31777 |
Artama (Phenytoin) (Controls exposed to Lamotrigine, sick), 2013 | Preterm birth (<37 gestational weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.72 [0.34;8.58] C excluded (control group) |
2/26 8/173 | 10 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9188 R31789 |
Artama (Phenytoin) (Controls unexposed, disease free), 2013 | Preterm birth (<37 gestational weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.85 [0.43;7.88] excluded (control group) |
2/26 30,027/719,509 | 30,029 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9190 R31813 |
Artama (Phenytoin) (Controls unexposed, sick), 2013 | Preterm birth (<37 gestational weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.52 [0.34;6.76] | 2/26 85/1,793 | 87 | 26 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9216 R31976 |
Pennell (Phenytoin), 2012 | Preterm Birth (< 37 weeks GA) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.88 [0.57;6.13] C | 6/55 6/98 | 12 | 55 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9263 R32124 |
Koch (Phenytoin), 1996 | Prematurity (< 37 weeks) | during pregnancy (anytime or not specified) | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 11.64 [0.97;139.55] C | 2/13 1/65 | 3 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 7 studies | 2.14 [0.99;4.62] | 491 | 108 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenytoin) (Controls unexposed, sick; 2: Phenytoin) (Mixed indications; 3: Phenytoin; 4: Phenytoin) (Controls unexposed, sick) (Mixed indications; 5: Phenytoin) (Controls unexposed, sick; 6: Phenytoin; 7: Phenytoin;
Asymetry test p-value = 0.4426 (by Egger's regression)
slope=0.2343 (0.6970); intercept=0.5585 (0.6702); t=0.8333; p=0.4426
excluded 9187, 9188, 9275, 9276, 9192